Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers

Area of Science:

• Oncology
• Biomarker Research
• Cancer Screening

Background:

• Breast cancer screening detects tumors early, but interval cancers arise between screenings.
• Identifying biological markers associated with interval cancers is crucial for improving screening strategies.

Purpose of the Study:

• To compare the expression of prognostic markers (estrogen receptor, progesterone receptor, p53, Ki67, c-erbB2) in screen-detected versus interval breast cancers.
• To identify specific biomarkers linked to the development of symptomatic breast cancer within the screening interval.

Main Methods:

• Immunohistochemistry was used to assess the expression of five key prognostic markers.
• A series of 51 interval and 84 screen-detected invasive breast tumors were analyzed.
• Multiple logistic regression analysis identified significant predictors of interval cancers.

Main Results:

• Interval cancers showed significantly lower estrogen receptor expression and higher expression of p53, Ki67, and c-erbB2 compared to screen-detected cancers.
• Ki67 and c-erbB2 expression levels were the most significant predictors, distinguishing interval from screen-detected tumors with 83% accuracy.
• High Ki67 expression suggests increased cell proliferation, while elevated c-erbB2 indicates a role for growth factor receptors in rapid interval cancer growth.

Conclusions:

• Ki67 and c-erbB2 are key biomarkers differentiating interval breast cancers from screen-detected ones.
• Increased cell proliferation (Ki67) and growth factor receptor activity (c-erbB2) likely contribute to the rapid development of interval cancers.
• These findings may inform strategies to detect or predict interval breast cancers more effectively.